Table. 1.

Kidney transplantation cases

Study Type of cancer Allograft outcome Checkpoint inhibitor Year from tx to ICI IS regimen Cancer response Interval between IS reduction and ICI initiation ICI to rejection time
Murakami et al. (2021) [15] cSCC 24, Melanoma 22, NSCLC 8, MCC 4, RCC 3, Bladder Ca.2, Others 6 Rejection in 29/69 (19HD) Pembrolizumab 29, Nivolumab 11, Cemiplimab 10, Atezolizumab 3, Avelumab 3, Ipilimumab 2, Combination 11 9.33 (4.1–15.6) Steroid, antimetabolite, mTORi, CNI, dynamic steroid+mTORi, etc. CR 5, PR 15, SD 13, PD 34, NA 4 NA
Lakhani et al. (2021) [22] cSCC No rejection Pembrolizumab 7 Tac 8 mg+MMF 1,000 mg+Pred 5 mg → everolimus+MMF 500 mg SD 5 mo
Tan et al. (2021) [23] Melanoma Rejected, HD Nivolumab 14 Tac+MMF+Pred → Tac+Pred CR 10 mo 15 day
Tsung et al. (2021) [24] cSCC No rejection Cemiplimab×13 NA Everolimus+Pred PR NA
cSCC No rejection Pembrolizumab×2 NA Everolimus+Pred PD NA
cSCC Rejected, no HD Cemiplimab×7 14.3 Tac+Pred SD NA 2 mo
cSCC No rejection Cemiplimab×5 NA Everolimus+Pred PR NA
Kumar et al. (2020) [25] facial SCC Rejected, reacted pulse Pembrolizumab 15 Tac+MMF+Pred → sirolimus+MMF+Pred CR NA 8 mo
Melanoma Rejected, reacted pulse Pembrolizumab 11 Tac+MMF+Pred → sirolimus+MMF SD NA 1 mo
Trager et al. (2020) [26] Melanoma No rejection Ipilimumab and nivolumab then nivolumab 3 Tac+sirolimus → sirolimus → off PR 1 mo
Melanoma Rejected, HD Pembrolizumab then ipilimumab+nivolumab 2 Tac+MMF+Pred → Pred PD 1 mo 1 mo
cSCC No rejection Cemiplimab then ipilimumab and nivolumab 13 Tac+sirolimus+MMF → sirolimus PR 2 mo
Melanoma Rejected, reacted pulse Nivolumab and ipilimumab 4 Sirolimus+MMF+Pred → sirolimus+Pred SD 1 mo
Venkatachalam et al. (2020) [27] cSCC Rejected, HD Pembrolizumab 3 Tac+Pred → everolimus+Pred PD Concurrent 8 wk
cSCC No rejection Pembrolizumab 22 CYA+MMF+Pred → CYA↓+Pred PD 6 wk NA
RCC AKI, no HD Nivolumab 2 Tac+MMF+Pred → Tac↓+Pred → everolimus+Pred PD NA 6 wk
Melanoma No rejection Pembrolizumab, then ipilimumab, then nivolumab 19 CYA+azathioprine+Pred → sirolimus+Pred PD 3 mo NA
Melanoma Rejected, HD Ipilimumab, then pembrolizumab 15 CYA+azathioprine+Pred → Pred PR NA 3 wk
LUAD No rejection Pembrolizumab 10 Tac+Pred → Pred PD Concurrent NA
Hurkmans et al. (2019) [21] Melanoma Rejected, HD Nivolumab×5 5 Tac+MMF → Pred 20 mg PD 1 wk 12 day
Zehou et al. (2018) [28] Melanoma No rejection Ipilimumab×4 2 Tac+MMF+Pred → everolimus+MMF+Pred PD Just before
Melanoma No rejection Ipilimumab×4 7 Tac+MMF+Pred → sirolimus+Pred PD 8 mo
Melanoma No rejection Ipilimumab×3 then nivolumab 6 Everolimus+azathioprine+Pred PD NA
Melanoma No rejection Ipilimumab×4 1 Tac+everolimus+Pred → MMF+everolimus↑+Pred↑ PD 1 mo
Melanoma Rejected, HD Ipilimumab×1 26 Everolimus+Pred → Pred SD 1 mo 27 day
Melanoma No rejection Ipilimumab×4 23 CYA+Pred → everolimus PR 8 mo
Barnett et al. (2017) [29] Duodenum adenocarcinoma No rejection Nivolumab 6 Tac+MMF+Pred → sirolimus+Pred SD 1 wk
Kittai et al. (2017) [30] cSCC No rejection Nivolumab 14 Tac+MMF → sirolimus SD NA
Kwatra et al. (2017) [31] Melanoma Rejected, BSC Pembrolizumab×2 13 Tac+MMF → azathioprine100 mg daily and everolimus 0.5 mg twice PD 1.5 mo
Alhamad et al. (2016) [32] Melanoma Rejected, HD Ipilimumab×4 then pembrolizumab 15 CYA+Pred → Pred PD NA 3 Weeks after pembrolizumab initiation
Boils et al. (2016) [33] NSCLC Rejected, HD Nivolumab×3 5 CYA+Pred → CYA (decreased)+Pred NA 2 yr NA
Herz et al. (2016) [34] Melanoma No rejection Ipilimumab then nivolumab 8 Tac+Pred PD NA
Jose et al. (2016) [35] Melanoma Rejected, HD Ipilimumab×2 16 Tac → Pred NA NA 1 mo
Lipson et al. (2016) [16,17] cSCC Rejected, HD Pembrolizumab 25 Pred 5 mg CR NA 2 mo
Ong et al. (2016) [36] Melanoma Rejected, HD Nivolumab 12 Tac+MMF+Pred → Pred 10 mg PR 2 mo 8 day
Spain et al. (2016) [37] Melanoma Rejected, HD Ipilimumab×4 then nivolumab 15 Tac+Pred → Pred 5 mg PR NA 8 Days after nivolumab initiation
Lipson et al. (2014) [12] Melanoma No rejection Ipilimumab 11 Tac+Pred → Pred 5 mg PR 6 wk
Melanoma No rejection Ipilimumab×4 8 Tac+MMF+Pred → Pred 5 mg PD 1 yr

tx, transplantation; ICI, immune checkpoint inhibitor; IS, immunosuppressant; cSCC, cutaneous squamous cell carcinoma; NSCLC, non-small cell lung cancer; MCC, Merkel cell carcinoma; RCC, renal cell carcinoma; HD, hemodialysis; mTORi, mammalian target of rapamycin inhibitor; CNI, calcineurin inhibitor; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; NA, not applicable; Tac, tacrolimus; MMF, mycophenolate mofetil; Pred, prednisone; CYA, cyclosporin A; AKI, acute kidney injury; LUAD, lung adenocarcinoma; BSC, best supportive care.

Korean J Transplant 2022;36:82~98 https://doi.org/10.4285/kjt.22.0013
© Korean Journal of Transplantation